














# BioCLIA<sup>®</sup> Autoimmune Control Set

**GBM**

## GBM Assay Controls

### Key to Symbols Used

	Catalog Number		Expiration Date
	For <i>In Vitro</i> Diagnostic Use		Lot Number
	Store between +2°C and +8°C		Consult Instruction for Use
	Manufacturer		Authorized Representative in European Union
	Control 1		Contains Sufficient for $< n >$ Tests
	Control 2		Chemical Risk Warning
			Biological Risk Warning

# BioCLIA® Autoimmune Control Set,

## GBM

### Intended Use

The BioCLIA Autoimmune Control Set, GBM is intended for the quality control purposes of the BioCLIA GBM performed on the BioCLIA® 1200 and BioCLIA® 6500.

### Catalog Numbers

MY00317 (2 X 1 mL)

MY00368 (4 X 1 mL)

### Summary and Principles of the Procedure

Serological detection of anti-neutrophil cytoplasmic antibodies (ANCA) contributes to the autoimmune diseases diagnosis include Wegener's granulomatosis, acute progressive glomerulonephritis, polyarteritis, ulcerative colitis, and primary sclerosing cholangitis. <sup>1, 2</sup> PR3, MPO and GBM are general indicators for the detection of ANCA, which can greatly improve the early diagnostic rate of renal vasculitis.

The main component of the glomerular basement membrane (GBM) is the extracellular matrix protein including type IV collagen, laminin, fibronectin and proteoglycans. The epitope of anti-GBM antibodies are located on the type IV collagen. Type IV collagen molecule is composed of three chains of 170 kDa. These chains form several triple-helix domains, and the domains are separated by the amino acid sequence which cannot form the helix. A tight spiral zone (7S domain) is located at the amino terminal and a spherical handle shaped structure (NC1 domain) at the carboxy terminal. The target antigen of anti-GBM antibodies is in NC1 domain of  $\alpha$ -3 (IV) chain.

Anti-GBM antibody is a serological indicator for all anti-GBM glomerulonephritis including Goodpasture's syndrome. <sup>3, 4</sup> In cases with no lung disorders, the positive rate of anti-GBM antibody is 60% while it is 80% - 90% in cases with lung disorders. Although the incidence of Goodpasture's syndrome is relatively low (only 0.5% of all kidney disorder patients), but the disease develop rapidly. If not treated well, the mortality rate will as high as 75-90%. <sup>5, 6</sup> Early diagnosis and proper treatment can significantly reduce the mortality.

### Materials supplied

- **GBM Control 1** A tube contains 1mL, ready to use reagent. Control 1 contains human antibodies to GBM in stabilizers and preservatives (Low).

GBM Control L

Preservatives: 0.0015% < Proclin 300 < 0.6%

- **GBM Control 2** A tube contains 1mL, ready to use reagent. Control 2 contains human antibodies to

GBM in stabilizers and preservatives (High).

GBM Control H

Preservatives: 0.0015% < Proclin 300 < 0.6%

Target value and acceptable range for the controls are indicated on control information sheet in each kit.

### Warnings and Precautions

The human derived material in this product was tested by FDA approved methods and found nonreactive for Hepatitis B Surface Antigen (HBsAg), Anti-HCV and HIV 1/2 antibodies. Handle as if potentially infectious. <sup>7</sup> Avoid contacting with skin and eyes. Do not empty into drains. Wear suitable protective clothing.

Precautions:



Human serum is added in the controls.



Proclin 300 is added in the controls at

concentration between 0.0015% - 0.6%.

- The product is for *in vitro* diagnostic use only.
- Do not use any controls beyond their expiration dates. Do not mix controls from different lots unless specified.
- Instructions must be carefully followed for using and storing of controls. Any modification in procedure may interfere with the results. Controls and contaminated vials must be handled strictly following safety guidelines or rules of biological hazards to ensure the users' and environmental safety.
- Controls contain chemical and biological components. Avoid ingesting or splashing onto skin and mucous membrane. If direct contact with controls happens, rinse the contact surface with plenty of water immediately and see a doctor if necessary.

### Storage Conditions

The kit is stable until the expiration date, if it is stored and handled as directed. Routine store the kit in refrigerator (2-8°C). Once a control tube is opened, it is good for a total of 15 times, no more than 2 hours per time when kept uncapped, onboard the instrument, after which the reagent must be discarded. Three freeze-thaw cycles before testing has no effect on the kit reagents.

### Assay Procedure

Note that, for obtaining optimal performance, it is important to perform all routine maintenance procedures as defined in the BioCLIA® 1200 and BioCLIA® 6500 User Manual.

See the BioCLIA® 1200 and BioCLIA® 6500 User Manual for preparation, setup, dilutions, adjustment, assay and quality control procedures.

The control procedure can be done before running

the specimens each day. Users also can adjust the control procedure period according to their own lab frequency.

#### **Limitations**

This product is designed as controls for monitoring the performance of the BioCLIA GBM. These controls are subjected to the limitations of the assay system. Deviations may indicate possible problems with one or more components in the test system.

#### **References**

1. Savige J, Davies D, Falk RJ, Jennette JC, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. *Kidney International* 2000;57:846-62.
2. Bossuyt X. Serologic markers in inflammatory bowel disease. *Clinical Chemistry* 2006;52:171-81.
3. Hellmark T, Johansson C, Wieslander J. Characterization of anti-GBM antibodies involved in Goodpasture's syndrome. *Kidney International* 1994;46:823-9.
4. Salama AD, Levy JB, Lightstone L, Pusey CD. Goodpasture's disease. *Lancet* 2001;358:917-20.
5. Herody M, Bobrie G, Gouarin C, Grünfeld JP, Noel LH. Anti-GBM disease: predictive value of clinical, histological and serological data. *Clinical Nephrology* 1993;40:249-55.
6. Kathuria P, Sanghera P, Stevenson FT, Sharma S, Lederer E, Lohr JW, Talavera F, et al. Goodpasture Syndrome Treatment & Management. Medscape Reference. 2013.
7. Richmond JY, McKinney RW. Biosafety in microbiological and biomedical laboratories: U.S.GPO. 1999.



HOB Biotech Group Co., Ltd



C6 Building, No. 218 Xinghu Road, Suzhou Industrial Park,  
Suzhou, Jiangsu, 215123, China

**REGISTRANT/MANUFACTURE:** HOB Biotech Group Co., Ltd

#### **ADDRESS/LOCATION:**

C6 Building, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, 215123 China

**CONTACT INFORMATION:** TEL (+86)512-69561996  
Fax (+86)512-62956652

**WEBSITE:** [www.hob-biotech.com](http://www.hob-biotech.com)

**CUSTOMER SERVICE:** HOB Biotech Group Co., Ltd

**CUSTOMER SERVICE CONTACT:** TEL (+86)4008601202



**EUROPE REPRESENTATIVE:** Emergo Europe

#### **ADDRESS/LOCATION:**

Prinsessegracht 20, 2514 AP The Hague, The Netherlands

#### **Technical Assistance**

For technical assistance, contact your National Distributor.

17<sup>th</sup> April 2019

Revision 9